8-K: iRhythm Technologies Reports Record Q2 2025 Revenue and Raises Full-Year Guidance

iRhythm Technologies, Inc. announced strong second quarter 2025 financial results, including record revenue and improved profitability, leading to an increase in its full-year 2025 financial guidance.

Summary

• Revenue for the second quarter of 2025 reached $186.7 million, marking a 26.1% increase compared to $148.0 million in the second quarter of 2024.
• Gross margin improved to 71.2% in Q2 2025, a 130-basis point increase from 69.9% in Q2 2024.
• Net loss for Q2 2025 decreased to $14.2 million, or $0.44 per diluted share, compared to a net loss of $20.1 million, or $0.65 per diluted share, in Q2 2024.
• Adjusted net loss for Q2 2025 was $10.2 million, or $0.32 per diluted share, a significant improvement from an adjusted net loss of $18.8 million, or $0.61 per diluted share, in Q2 2024.
• Adjusted EBITDA for Q2 2025 was $15.7 million, up from $5.0 million in Q2 2024.
• Unrestricted cash, cash equivalents, and marketable securities stood at $545.5 million as of June 30, 2025.
• The company increased its fiscal year 2025 revenue guidance to a range of $720 million to $730 million.
• Adjusted EBITDA margin for fiscal year 2025 is now expected to range from approximately 8.0% to 8.5% of revenues.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook with strong financial results, increased guidance, strategic partnerships, and positive clinical evidence. The significant revenue growth, improved profitability metrics, and robust cash position contribute to a very favorable sentiment.

Positives

• Achieved record quarterly revenue of $186.7 million in Q2 2025, representing 26.1% year-over-year growth.
• Improved gross margin by 130 basis points to 71.2% due to volume leverage and operational efficiencies.
• Significantly reduced net loss to $14.2 million and adjusted net loss to $10.2 million compared to the prior year, indicating progress towards profitability.
• Strong cash position with $545.5 million in unrestricted cash, cash equivalents, and marketable securities.
• Increased full-year 2025 guidance for both revenue and adjusted EBITDA margin, reflecting confidence in continued performance.
• Continued momentum in core long-term continuous monitoring business and sustained demand for Zio AT.
• Successful expansion with innovative value-based care partners and contribution from international markets.
• Executed a strategic partnership with Lucem Health to accelerate AI-driven early disease detection for arrhythmias.
• Presented positive results from two large-scale real-world studies at ADA 2025, highlighting the importance of early cardiac detection in at-risk populations.

Negatives

• The company continues to report a net loss, although it has decreased year-over-year.
• Operating expenses increased to $151.6 million in Q2 2025, primarily driven by funding new development activities and incremental costs to serve a growing global patient volume.

Future Outlook

The company projects full-year 2025 revenue to be between $720 million and $730 million, an increase from previous guidance. Adjusted EBITDA margin for the full year 2025 is expected to range from approximately 8.0% to 8.5% of revenues. The company anticipates continued growth driven by its core monitoring business, Zio AT penetration, and expansion with value-based care partners, further supported by its AI partnership and clinical evidence.

Management Comments

• "The second quarter of 2025 was another record quarter for iRhythm, with growth of more than 26%, showcasing the strength of our diversified growth strategy."
• "Our continued momentum spans three key areas: accelerating growth in our core monitoring business, continued penetration of Zio AT across major health systems, and successful expansion with innovative value-based care partners."
• "With strong execution, combined with our transformative AI partnership with Lucem Health and the growing abundance of compelling clinical evidence, were uniquely positioned to revolutionize early cardiac detection and create substantial value for patients, providers, and shareholders while addressing the growing need for preventative care."

Industry Context

iRhythm's strong performance, particularly in its core long-term continuous monitoring business and the expansion of Zio AT, aligns with the broader trend of increasing demand for remote patient monitoring and digital health solutions. The strategic partnership with Lucem Health for AI-driven early disease detection positions iRhythm at the forefront of leveraging artificial intelligence to enhance diagnostic capabilities and move towards more predictive and preventative healthcare models, a key area of innovation in the medical technology sector. The clinical study results presented at ADA 2025 further underscore the growing recognition of the link between cardiometabolic conditions and arrhythmias, highlighting a significant market opportunity for early detection strategies.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, and strategic initiatives that could drive future value.
• Patients: Positive impact through continued innovation in cardiac detection and prevention, including the AI partnership and clinical evidence supporting early detection.
• Providers: Positive impact through continued availability and penetration of Zio services and Zio AT, offering advanced diagnostic tools.
• Employees: Continued growth and strategic partnerships may indicate job stability and potential for expansion.

Next Steps

• iRhythm's management team will host a conference call on July 31, 2025, at 1:30 p.m. PT/4:30 p.m. ET to discuss the results.
• The company expects to file its Form 10-Q on or about July 31, 2025, which will contain more detailed risk factors and financial information.

Key Dates

Recommendation

The company delivered robust financial results for Q2 2025, demonstrating significant revenue growth, improved gross margins, and a notable reduction in net loss. The increased full-year guidance for both revenue and adjusted EBITDA margin signals strong operational momentum and management confidence. Strategic initiatives, such as the AI partnership with Lucem Health and positive clinical study outcomes, enhance the company's competitive position and long-term growth prospects in the digital healthcare and cardiac monitoring market. The strong cash position provides financial flexibility. These factors collectively suggest a positive trajectory for the company, making it an attractive investment.

Keywords

Digital Healthcare, Cardiac Monitoring, Arrhythmia Detection, Zio AT, Wearable Biosensors, Cloud-based Data Analytics, AI in Healthcare, Cardiometabolic Health, Preventative Care, Medical Devices